TG THERAPEUTICS, INC. (TGTX): debt financing — TG Therapeutics establishes $750M term loan facility due 2031, repays prior term loans

TG THERAPEUTICS, INC.

Borrowed $750M on March 18, 2026 under new term loan; proceeds used to fully repay initial term loans.
Loan matures March 18, 2031; interest rate is SOFR + margin starting at 4.75% (or base rate + 3.75%).
Quarterly amortization payments of $37.5M begin Q1 2030; can be deferred if leverage ratio met.
Also established uncommitted additional facility of up to $250M.
Loan secured by substantially all assets of borrower and guarantors; includes customary covenants.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

TG THERAPEUTICS, INC. incurred term loan of $750 million with Blue Owl Capital Corporation at an applicable margin plus, at the Borrower’s option, either (a) a base rate dete maturing March 18, 2031.

Instrument: term loan
Principal: $750 million
Counterparty: Blue Owl Capital Corporation
Rate: an applicable margin plus, at the Borrower’s option, either (a) a base rate dete
Maturity: March 18, 2031
Event: incurrence

Exact text from the filing

the Borrower established (i) a $750 million term loan facility (the “2026 Term Loan”), which was borrowed in full on the Closing Date

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

TG THERAPEUTICS, INC. amended First Amendment with Blue Owl Capital Corporation, as administrative agent, and the lenders party thereto valued at $750 million term loan facility (effective 2026-03-18).

Action: amendment
Agreement: credit facility
Counterparty: Blue Owl Capital Corporation, as administrative agent, and the lenders party thereto
Value: $750 million term loan facility
Effective: 2026-03-18

Exact text from the filing

On March 18, 2026 (the “Closing Date”), the Company (the “Borrower”) entered into the first amendment agreement, dated as of the Closing Date (the “First Amendment”), by and among the Borrower, certain subsidiaries of the Borrower, as guarantors, the lenders party thereto and Blue Owl Capital Corporation, as administrative agent (the “Administrative Agent”), which amends the financing agreement, dated as of August 2, 2024

View on SEC.gov

Browse all debt financings →

TG THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-26-009253

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.